The manufacturer should submit a safety specification and pharmacovigilance plan at the time of submission of the marketing authorization application. The principles of pharmacovigilance planning can be found in relevant guidelines such as ICH E2E11. The safety specification should describe important identified or potential safety issues for the RBP, the substance class and/or any that are specific for the SBP. The pharmacovigilance plan should describe the planned post- marketing activities and methods based on the safety specification11. In some cases, risk minimization measures such as educational material for patients and/or treating physicians may enhance the safe use of the SBP.